WallStSmart

NVIDIA Corporation (NVDA)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

NVIDIA Corporation generates 3900% more annual revenue ($215.94B vs $5.40B). NVDA leads profitability with a 55.6% profit margin vs 27.5%. NVDA appears more attractively valued with a PEG of 0.72. NVDA earns a higher WallStSmart Score of 79/100 (B+).

NVDA

Strong Buy

79

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 9.3Quality: 8.5
Piotroski: 3/9Altman Z: 6.75

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVDAUndervalued (+23.6%)

Margin of Safety

+23.6%

Fair Value

$229.32

Current Price

$178.68

$50.64 discount

UndervaluedFair: $229.32Overvalued
RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVDA6 strengths · Avg: 10.0/10
Market CapQuality
$4.26T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
101.5%10/10

Every $100 of equity generates 101 in profit

Profit MarginProfitability
55.6%10/10

Keeps 56 of every $100 in revenue as profit

Operating MarginProfitability
65.0%10/10

Strong operational efficiency at 65.0%

Revenue GrowthGrowth
73.2%10/10

Revenue surging 73.2% year-over-year

EPS GrowthGrowth
95.6%10/10

Earnings expanding 95.6% YoY

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

Areas to Watch

NVDA3 concerns · Avg: 3.0/10
P/E RatioValuation
35.7x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
27.6x2/10

Trading at 27.6x book value

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : NVDA

The strongest argument for NVDA centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 55.6% and operating margin at 65.0%. Revenue growth of 73.2% demonstrates continued momentum.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bear Case : NVDA

The primary concerns for NVDA are P/E Ratio, Piotroski F-Score, Price/Book.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

NVDA profiles as a growth stock while RMD is a mature play — different risk/reward profiles.

NVDA carries more volatility with a beta of 2.38 — expect wider price swings.

NVDA is growing revenue faster at 73.2% — sustainability is the question.

NVDA generates stronger free cash flow (34.9B), providing more financial flexibility.

Bottom Line

NVDA scores higher overall (79/100 vs 70/100), backed by strong 55.6% margins and 73.2% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

NVIDIA Corporation

TECHNOLOGY · SEMICONDUCTORS · USA

Nvidia Corporation is an American multinational technology company incorporated in Delaware and based in Santa Clara, California. It designs graphics processing units (GPUs) for the gaming and professional markets, as well as system on a chip units (SoCs) for the mobile computing and automotive market.

Visit Website →

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?